These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 20684886

  • 1. Enzyme replacement therapy "drug holiday": results from an unexpected shortage of an orphan drug supply in Australia.
    Goldblatt J, Fletcher JM, McGill J, Szer J, Wilson M.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):107-10. PubMed ID: 20684886
    [Abstract] [Full Text] [Related]

  • 2. Interruption of enzyme replacement therapy in Gaucher disease.
    Goldblatt J, Fletcher JM, McGill J, Szer J, Wilson M.
    S Afr Med J; 2016 May 25; 106(6 Suppl 1):S79-81. PubMed ID: 27245534
    [Abstract] [Full Text] [Related]

  • 3. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.
    Hollak CE, vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, Collin-Histed T, Deegan P, van Dussen L, Giraldo P, Mengel E, Michelakakis H, Manuel J, Hrebicek M, Parini R, Reinke J, di Rocco M, Pocovi M, Sa Miranda MC, Tylki-Szymanska A, Zimran A, Cox TM.
    Blood Cells Mol Dis; 2010 Jan 15; 44(1):41-7. PubMed ID: 19804996
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
    Giraldo P, Irún P, Alfonso P, Dalmau J, Fernández-Galán MA, Figueredo A, Hernández-Rivas JM, Julia A, Luño E, Marín-Jimenez F, Martín-Nuñez G, Montserrat JL, de la Serna J, Vidaller A, Villalón L, Pocovi M.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):115-8. PubMed ID: 20934891
    [Abstract] [Full Text] [Related]

  • 5. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN.
    J Bone Miner Res; 2007 Jan 15; 22(1):119-26. PubMed ID: 17032149
    [Abstract] [Full Text] [Related]

  • 6. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM, Petakov M, Giraldo P, Rosenbaum H, Szer J, Deegan PB, Amato DJ, Mengel E, Tan ES, Chertkoff R, Brill-Almon E, Zimran A.
    Blood Cells Mol Dis; 2014 Dec 15; 53(4):253-60. PubMed ID: 24950666
    [Abstract] [Full Text] [Related]

  • 7. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
    El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, Batista JL, Cox GF, Mistry PK.
    Mol Genet Metab; 2017 Dec 15; 120(1-2):47-56. PubMed ID: 28040394
    [Abstract] [Full Text] [Related]

  • 8. Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1.
    Stirnemann J, Rose C, Serratrice C, Dalbies F, Lidove O, Masseau A, Pers YM, Baron C, Belmatoug N.
    Orphanet J Rare Dis; 2015 May 13; 10():62. PubMed ID: 25968608
    [Abstract] [Full Text] [Related]

  • 9. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep 13; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 10. Gaucher disease, enzyme replacement therapy, and the Patient Assistance Program.
    Goldwater RS.
    J Intraven Nurs; 1996 Sep 13; 19(2):83-8. PubMed ID: 8852168
    [Abstract] [Full Text] [Related]

  • 11. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb 13; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 12. Individualization of long-term enzyme replacement therapy for Gaucher disease.
    Andersson HC, Charrow J, Kaplan P, Mistry P, Pastores GM, Prakash-Cheng A, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, International Collaborative Gaucher Group U.S. Regional Coordinators.
    Genet Med; 2005 Feb 13; 7(2):105-10. PubMed ID: 15714077
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
    Elstein D, Mehta A, Hughes DA, Giraldo P, Charrow J, Smith L, Shankar SP, Hangartner TN, Kunes Y, Wang N, Crombez E, Zimran A.
    Am J Hematol; 2015 Jul 13; 90(7):592-7. PubMed ID: 25776130
    [Abstract] [Full Text] [Related]

  • 14. The management of Gaucher disease in developing countries: a successful experience in Southern Brazil.
    Krug BC, Schwartz IV, Lopes de Oliveira F, Alegra T, Campos Martins NL, Todeschini LA, Picon PD.
    Public Health Genomics; 2010 Jul 13; 13(1):27-33. PubMed ID: 19407439
    [Abstract] [Full Text] [Related]

  • 15. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
    Kishnani PS, DiRocco M, Kaplan P, Mehta A, Pastores GM, Smith SE, Puga AC, Lemay RM, Weinreb NJ.
    Mol Genet Metab; 2009 Apr 13; 96(4):164-70. PubMed ID: 19195916
    [Abstract] [Full Text] [Related]

  • 16. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M, Barzegar S, Pan L, Shi P, Oommen S, Durant J, Ruiz JA.
    J Immunol Methods; 2011 Oct 28; 373(1-2):45-53. PubMed ID: 21846471
    [Abstract] [Full Text] [Related]

  • 17. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
    Smith L, Rhead W, Charrow J, Shankar SP, Bavdekar A, Longo N, Mardach R, Harmatz P, Hangartner T, Lee HM, Crombez E, Pastores GM.
    Mol Genet Metab; 2016 Feb 28; 117(2):164-71. PubMed ID: 26043810
    [Abstract] [Full Text] [Related]

  • 18. The long-term international safety experience of imiglucerase therapy for Gaucher disease.
    Starzyk K, Richards S, Yee J, Smith SE, Kingma W.
    Mol Genet Metab; 2007 Feb 28; 90(2):157-63. PubMed ID: 17079176
    [Abstract] [Full Text] [Related]

  • 19. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
    Elstein D, Altarescu G, Maayan H, Phillips M, Abrahamov A, Hadas-Halpern I, Tiomkin M, Zimran A.
    Blood Cells Mol Dis; 2012 Jan 15; 48(1):45-50. PubMed ID: 22047948
    [Abstract] [Full Text] [Related]

  • 20. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
    Heitner R, Arndt S, Levin JB.
    S Afr Med J; 2004 Aug 15; 94(8):647-51. PubMed ID: 15352589
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.